Single Nucleotide Polymorphisms in Selected Apoptotic Genes and BPDE-Induced Apoptotic Capacity in Apparently Normal Primary Lymphocytes: A Genotype-Phenotype Correlation Analysis.
Apoptotic capacity (AC) in primary lymphocytes may be a marker for cancer susceptibility, and functional single nucleotide polymorphisms (SNPs) in genes involved in apoptotic pathways may modulate cellular AC in response to DNA damage. To further examine the correlation between apoptotic genotypes and phenotype, we genotyped 14 published SNPs in 11 apoptosis-related genes (i.e., p53, Bcl-2, BAX, CASP9, DR4, Fas, FasL, CASP8, CASP10, CASP3, and CASP7) and assessed the AC in response to benzo[a]pyrene-7,8-9,10-diol epoxide (BPDE) in cultured primary lymphocytes from 172 cancer-free subjects. We found that among these 14 SNPs, R72P, intron 3 16-bp del/ins, and intron 6 G>A in p53, -938C>A in Bcl-2, and I522L in CASP10 were significant predictors of the BPDE-induced lymphocytic AC in single-locus analysis. In the combined analysis of the three p53 variants, we found that the individuals with the diplotypes carrying 0-1 copy of the common p53 R-del-G haplotype had higher AC values compared to other genotypes. Although the study size may not have the statistical power to detect the role of other SNPs in AC, our findings suggest that some SNPs in genes involved in the intrinsic apoptotic pathway may modulate lymphocytic AC in response to BPDE exposure in the general population. Larger studies are needed to validate these findings for further studying individual susceptibility to cancer and other apoptosis-related diseases.
Hu
Zhibin
Z
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Li
Chunying
C
Chen
Kexin
K
Wang
Li-E
LE
Sturgis
Erich M
EM
Spitz
Margaret R
MR
Wei
Qingyi
Q
Nat Genet. 2003 Mar;33(3):357-65
12567188
Toxicol Appl Pharmacol. 1998 Aug;151(2):367-76
9707513
Prostate Cancer Prostatic Dis. 2006;9(3):284-92
16733517
Mol Immunol. 1997 Jun;34(8-9):577-82
9393960
Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1169-77
17637392
J Natl Cancer Inst. 2004 Dec 15;96(24):1866-9
15601643
Science. 1998 Oct 9;282(5387):290-3
9765154
CA Cancer J Clin. 2005 May-Jun;55(3):178-94
15890640
Science. 1995 Mar 10;267(5203):1456-62
7878464
Bioinformatics. 2001 Sep;17(9):838-9
11590100
Hum Mutat. 2006 Mar;27(3):242-8
16419081
J Natl Cancer Inst. 2000 Nov 1;92(21):1764-72
11058619
Am J Hum Genet. 2003 Nov;73(5):1162-9
14574645
Semin Hematol. 1997 Oct;34(4 Suppl 5):9-19
9408956
Nature. 1983 Jun 9-15;303(5917):468-72
6304528
Cancer Lett. 2002 Sep 26;183(2):123-30
12065086
Cancer Res. 1998 Apr 15;58(8):1593-8
9563466
Hum Pathol. 1996 Feb;27(2):102-10
8617450
Carcinogenesis. 1995 Sep;16(9):2117-24
7554063
Nature. 2004 Nov 18;432(7015):307-15
15549092
Cancer Lett. 2002 Dec 10;187(1-2):199-205
12359369
Mol Cell Biol. 1999 Feb;19(2):1092-100
9891044
J Immunol. 2003 Jan 1;170(1):132-8
12496392
Cancer Res. 1985 Jan;45(1):51-6
3155495
Hum Immunol. 2003 Feb;64(2):285-9
12559631
Toxicology. 2004 Jun 1;199(1):35-46
15125997
Cancer Res. 2003 Mar 15;63(6):1157-9
12649168
Trends Genet. 1995 Mar;11(3):101-5
7732571
Cancer Res. 1998 May 15;58(10):2102-6
9605752
J Pathol. 1996 May;179(1):10-4
8691332
J Cell Biol. 1994 Jan;124(1-2):1-6
8294493
J Rheumatol. 2002 Jun;29(6):1183-8
12064832
J Natl Cancer Inst. 2004 Jul 7;96(13):1030-6
15240787
Physiol Rev. 1980 Oct;60(4):1107-66
7001511
Carcinogenesis. 2000 Mar;21(3):485-95
10688869
J Hum Genet. 2004;49(8):449-454
15278764
Science. 2004 Jul 30;305(5684):626-9
15286356
Science. 1998 Aug 28;281(5381):1305-8
9721089
Genes Immun. 2001 Apr;2(2):117-8
11393657
Nature. 2001 May 17;411(6835):342-8
11357141
Cell. 1995 Jan 27;80(2):293-9
7834749
Clin Cancer Res. 2001 Jun;7(6):1688-97
11410508
Lung Cancer. 2003 Oct;42(1):1-8
14512182
J Natl Cancer Inst. 2002 May 1;94(9):681-90
11983757